Skip to main content

Frazier Healthcare Partners — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

50
Companies
$3.9B
Total invested
$96.2M
Avg. check
14
Industries
Biotechnology 21Health Care 13Pharmaceutical 10Therapeutics 9Biopharma 7Life Science 6+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 50
Semnur Pharmaceuticals
September 2025

Semnur Pharmaceuticals is a specialty pharmaceutical company focusing on clinical and commercial development of innovative products.

Biotechnology · Los Altos$100.0M Post-IPO Equity
Iterum Therapeutics
August 2025

Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives.

Medical · Dublin$2.2M Post-IPO Equity
Allena Pharmaceuticals
May 2022

Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.

Biotechnology · Newton$2.8M Post-IPO Equity
Krystal Biotech
May 2023

Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..

Biopharma · Pittsburgh$160.0M Post-IPO Equity
Seraxis
May 2025

Seraxis is a privately owned biotechnology company.

Biotechnology · GermantownGrant
Mirum Pharmaceuticals
May 2026

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

Biotechnology · Foster City$600.0M Post-IPO Debt
Gritstone bio
April 2024

Gritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.

Biotechnology · Emeryville$32.5M Post-IPO Equity
Scholar Rock
March 2026

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Biopharma · Cambridge$100.0M Post-IPO Debt
Dascena
March 2022

Dascena develops machine learning algorithms to enable early disease intervention and improve care outcomes for patients.

Big Data · HoustonGrant
Tarsus Pharmaceuticals
March 2025

Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.

Biopharma · Irvine$125.0M Post-IPO Equity
Moximed
August 2024

Moximed develops innovative therapies for patients with knee osteoarthritis.

Biotechnology · Hayward$61.0M Series D
Lassen Therapeutics
December 2023

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Biotechnology · San Diego$85.0M Series B
Radionetics Oncology
August 2023

Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.

Health Care · California City$52.5M Series A
Phathom Pharmaceuticals
January 2026

Phathom Pharmaceuticals is a biopharmaceutical company.

Biotechnology · Florham Park$130.0M Post-IPO Equity
Vaxcyte
January 2026

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Biopharma · San Carlos$632.5M Post-IPO Equity
Iolyx Therapeutics
December 2025

Iolyx Therapeutics is a biotechnology research and healthcare service provider for ocular diseases.

Biopharma · Menlo Park$15.0M Series B
Pardes Biosciences
December 2021

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.

Biotechnology · Carlsbad$75.0M Post-IPO Equity
Immunovant
December 2025

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

Biopharma · New York$550.0M Post-IPO Equity
Rocket Pharmaceuticals
December 2024

Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.

Biotechnology · Cranbury$165.0M Post-IPO Equity
New Amsterdam Pharma
December 2024

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Biotechnology · Naarden$452.6M Post-IPO Equity
Sonoma Biotherapeutics
November 2025

Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.

Biotechnology · South San Francisco$300K Grant
Aptinyx
November 2022

Aptinyx Inc. is a biopharmaceutical company.

Biopharma · Evanston$5.6M Grant
Scilex Holding Company
November 2025

Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.

Health Care · Palo Alto$20.3M Post-IPO Equity
Scout Bio
October 2021

Scout Bi is a biotechnology company that specializes in veterinary, animal health, and gene therapy.

Biotechnology · Philadelphia$33.0M Series B

Where Frazier Healthcare Partners invests

Biotechnology21
Health Care13
Pharmaceutical10
Therapeutics9
Biopharma7
Life Science6

About Frazier Healthcare Partners's portfolio

How many companies has Frazier Healthcare Partners invested in?

Frazier Healthcare Partners has invested in 50 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Frazier Healthcare Partners invest in?

Frazier Healthcare Partners's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Biopharma. The firm invests across 14 different industry categories.

What is Frazier Healthcare Partners's largest investment?

Among tracked funding rounds, Vaxcyte received $632.5M in a Post-IPO Equity round. Frazier Healthcare Partners's total known invested capital is $3.9B.

What is the average investment size for Frazier Healthcare Partners?

Frazier Healthcare Partners's average investment size is $96.2M across its portfolio of 50 companies.

What are Frazier Healthcare Partners's most recent investments?

Recent Frazier Healthcare Partners portfolio additions include Semnur Pharmaceuticals, Iterum Therapeutics, Allena Pharmaceuticals, Krystal Biotech, Seraxis. These companies were founded in 2020 or later.

Reach the founders behind these 50 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →